Midazolam

May 27, 2020

CAPS® Expands Product Line to Address Drugs in Short Supply in the US: Launches Three New Products for the Treatment of Critically Ill Ventilated Patients

Nov 25, 2019

UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.

May 20, 2019

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.

Oct 25, 2018

DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings

Aug 13, 2018

FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters

Apr 20, 2018

UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

Mar 27, 2018

Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

Dec 27, 2017

PharMEDium Services, LLC Issues Voluntary Nationwide Recall of Certain Lots of Compounded Sterile Products due to Lack of Sterility Assurance

Dec 22, 2017

Information Update - New warnings regarding the use of certain sedative and anesthetic drugs during pregnancy and in early childhood